Notable Downgrades: Valeant (VRX), Juniper (JNPR), Intel (INTC), NetApp (NTAP)

Analysts at Barclays downgraded Valeant Pharmaceuticals International, Inc. (VRX) from ‘Overweight’ to ‘Equal Weight’ in a research report issued to clients on Monday. The target price for VRX is lowered from $135 to $34. Shares of the $10.04 billion market cap company are down 86.65% year-over-year and 73.46% year-to-date. VRX rose $2.46 to $29.44 in […] View the full post at: Notable Downgrades: Valeant (VRX), Juniper (JNPR), Intel (INTC), NetApp (NTAP) Related posts: Intel (INTC) Gets A Big European Fine NetApp Reluctant to Give Guidance Intel Raises Third-Quarter Outlook